RCKT · Rocket Pharmaceuticals, Inc.
$2.61
+0.05 (+1.95%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$284.87M
Shares
109.77M
Volume · Oct 5
1.66M
Avg daily vol (3M)
1.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.61
Open$2.59
Day$2.50–2.63
52W close$2.56–5.30
Avg vol 30d1.8M
Short int14.8M · 13.5% float · 11.1d
Short vol50%
Last earningsMar 27, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held Aug 9, 2021
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$17.25M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$283.75M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.1%
Year over year · more shares
Price change (1Y)
-20.2%
Trailing year
Short interest
13.5%
Latest settlement · 11.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
−22%
below
RSI (14)
30
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−32%
trailing
6-month return
−28%
trailing
YTD return
−26%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$432.5K over 90 days · 100% sells
Short interest
Rising
13.53% of float · ▲ +0.9% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
187 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+26%
Y/Y
Free cash flow
$-190.5M
Quant / Vol
risk profile
Volatility
72%
annualized · 1-yr
Max drawdown
−52%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
−22%
Bearish
RSI (14)
30
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$432.5K over 90 days · 100% sells
Short interest
Rising
13.53% of float · ▲ +0.9% MoM · 11.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
187 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 2%
Range high $5
vs 200-day avg -27%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCKT
this stock
Rocket Pharmaceuticals, Inc.
|
$284.87M | -25.6% | — | — | 13.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCKT | +0.0% | -32.4% | -28.3% | -0.8% | -25.6% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.2% | -33.0% | -39.9% | -2.4% | -39.3% |